Global Pneumococcal Vaccines Market Size By Type (PPSV 23, PCV 7/13), By Application (For Infants, For Children (2-10)), By Region, And Segment Forecasts, 2023 to 2032

The Global Pneumococcal Vaccines Market was valued at USD 9.1 billion in 2023 and is projected to reach USD 15.6 billion by 2031, growing at a CAGR of 6.9% during the forecast period from 2023 to 2031. The growth is driven by the rising prevalence of pneumococcal infections, increasing vaccination coverage across both pediatric and adult populations, and strong support from governmental and non-governmental immunization programs. Heightened awareness of vaccine-preventable diseases, coupled with global health initiatives, is propelling market expansion across both developed and developing economies.

Drivers:

Increasing Global Immunization Initiatives:

Efforts by the World Health Organization (WHO), Gavi, and UNICEF to introduce pneumococcal conjugate vaccines (PCVs) in low- and middle-income countries have significantly boosted market demand. National immunization programs are also expanding adult vaccine coverage, further strengthening growth.

Rising Incidence of Pneumonia and Related Diseases:

Pneumococcal bacteria are among the leading causes of pneumonia, meningitis, and sepsis. The increasing global burden of these diseases is prompting healthcare systems to adopt preventive measures, primarily through vaccination.

Strong Pipeline and Technological Advancements:

Companies are investing heavily in R&D to develop higher-valency pneumococcal vaccines that provide broader protection. Advances in vaccine delivery systems and thermostable formulations are further enhancing accessibility and adoption.

Restraints:

High Cost of Vaccines in Low-Income Countries:

Despite subsidies and aid programs, the high production cost of pneumococcal vaccines, particularly conjugate formulations, can be prohibitive for some healthcare systems, limiting penetration in cost-sensitive regions.

Limited Awareness in Certain Populations:

Although awareness has improved significantly, some populations, particularly in rural or underserved regions, still lack education regarding the importance of adult immunization against pneumococcal disease.

Opportunity:

Growth in Geriatric and At-Risk Populations:

With the aging global population and increased incidence of comorbidities like diabetes and chronic respiratory diseases, there is a heightened focus on vaccinating elderly and immunocompromised individuals—creating new avenues for market expansion.

Emergence of Combination Vaccines:

The development of combination vaccines that offer protection against multiple pathogens, such as pneumococcus, influenza, and RSV, represents a lucrative opportunity for manufacturers to expand their portfolio and improve compliance rates.

Market by System Type Insights:

Pneumococcal Conjugate Vaccines (PCV) dominated the market in 2023, accounting for the highest share due to their effectiveness in infants and young children. These vaccines offer protection against multiple serotypes and have demonstrated strong herd immunity benefits. The Pneumococcal Polysaccharide Vaccines (PPSV) segment also maintains significant demand, especially in adult and geriatric populations. Innovations in multivalent PCVs are expected to maintain the dominance of this segment over the forecast period.

Market by End-use Insights:

Pediatric Segment accounted for the largest market share in 2023, driven by national infant immunization programs and WHO recommendations for routine vaccination in children. However, the Adult and Geriatric Segment is anticipated to grow at the fastest rate, spurred by increasing awareness of adult pneumococcal disease, particularly among individuals with chronic conditions and the elderly population.

Market by Regional Insights:

North America led the market in 2023, owing to well-established immunization infrastructure, high awareness levels, and favorable reimbursement policies. Asia-Pacific is projected to be the fastest-growing region during the forecast period, driven by increasing government investments in public health, rising birth rates, and expanding vaccine access initiatives in countries like India and China. Europe continues to be a strong market due to robust healthcare systems and rising geriatric vaccination rates.

Competitive Scenario:

Key players in the Global Pneumococcal Vaccines Market include Pfizer Inc., GlaxoSmithKline plc, Merck & Co., Inc., Serum Institute of India Pvt. Ltd., SK Bioscience, Walvax Biotechnology Co., Ltd., and Affinivax Inc. These companies are focused on expanding their product portfolios, increasing manufacturing capacity, and securing regulatory approvals for next-generation vaccines.

Key Developments:

In 2024, Pfizer received regulatory approval for its 20-valent PCV in several key markets, offering broader serotype protection.

GlaxoSmithKline launched a strategic partnership with a global health agency in 2023 to expand access to pediatric PCVs in sub-Saharan Africa.

Serum Institute of India initiated clinical trials in 2023 for a low-cost, 15-valent PCV targeting underserved regions.

Scope of Work – Global Pneumococcal Vaccines Market

Report Metric Details

Market Size (2023) USD 9.1 billion

Projected Market Size (2031) USD 15.6 billion

CAGR (2023–2031) 6.9%

Market Segments By Vaccine Type (PCV, PPSV), By End-Use (Pediatric, Adult), By Region

Growth Drivers Immunization Programs, Increasing Disease Incidence, Strong R&D Pipeline

Opportunities Geriatric Vaccination, Combination Vaccines, Emerging Markets

Key Market Developments:

2024: Pfizer’s 20-valent pneumococcal conjugate vaccine gains approval in Europe and North America.

2023: Serum Institute launches trials for a 15-valent PCV aimed at low-income nations.

2023: GSK collaborates with global health organizations to increase access to pediatric PCVs in Africa.

FAQs:

1) What is the current market size of the Global Pneumococcal Vaccines Market?

The market was valued at USD 9.1 billion in 2023.

2) What is the major growth driver of the Global Pneumococcal Vaccines Market?

Key drivers include increasing global immunization initiatives and rising disease prevalence.

3) Which is the largest region during the forecast period in the Global Pneumococcal Vaccines Market?

North America held the largest market share in 2023.

4) Which segment accounted for the largest market share in Global Pneumococcal Vaccines Market?

The Pediatric segment dominated the market in terms of end-use in 2023.

5) Who are the key market players in the Global Pneumococcal Vaccines Market?

Key players include Pfizer Inc., GlaxoSmithKline plc, Merck & Co., Serum Institute of India, and SK Bioscience.